Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
210 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ewing Sarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape. Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 1 and 2 molecules, respectively.Ewing Sarcoma. Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Ewing Sarcoma Overview 8 Therapeutics Development 9 Pipeline Products for Ewing Sarcoma - Overview 9 Pipeline Products for Ewing Sarcoma - Comparative Analysis 10 Ewing Sarcoma - Therapeutics under Development by Companies 11 Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 13 Ewing Sarcoma - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Ewing Sarcoma - Products under Development by Companies 16 Ewing Sarcoma - Products under Investigation by Universities/Institutes 18 Ewing Sarcoma - Companies Involved in Therapeutics Development 19 Astellas Pharma Inc. 19 Cebiotex, S.L. 20 Celgene Corporation 21 EntreChem, S.L. 22 Exelixis, Inc. 23 Gradalis Inc. 24 Kolltan Pharmaceuticals, Inc. 25 Merck & Co., Inc. 26 Merrimack Pharmaceuticals, Inc. 27 NanoSmart Pharmaceuticals, Inc. 28 Nanovalent Pharmaceuticals Inc. 29 NantKwest, Inc. 30 Novartis AG 31 Oncomatryx Biopharma, S.L. 32 Oncternal Therapeutics, Inc. 33 Pfizer Inc. 34 Pharma Mar, S.A. 35 Recombio S.L 36 Shionogi & Co., Ltd. 37 Tesaro, Inc. 38 Ewing Sarcoma - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 43 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 axitinib - Drug Profile 50 cabozantinib s-malate - Drug Profile 56 CEB-01 - Drug Profile 74 Cellular Immunotherapy for Oncology - Drug Profile 75 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 77 celyvir - Drug Profile 78 Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 79 EC-8042 - Drug Profile 80 EC-8105 - Drug Profile 81 everolimus - Drug Profile 82 gemogenovatucel-T - Drug Profile 94 haNK Program - Drug Profile 98 irinotecan hydrochloride - Drug Profile 99 KITSG-3227 - Drug Profile 110 KTN-0182A - Drug Profile 111 linsitinib - Drug Profile 112 lurbinectedin - Drug Profile 114 Monoclonal Antibody Conjugate for Ewing Sarcoma - Drug Profile 121 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 122 niraparib - Drug Profile 123 NV-101 - Drug Profile 129 OMTX-503 - Drug Profile 130 OMTX-703 - Drug Profile 131 ONC-206 - Drug Profile 132 paclitaxel albumin bound - Drug Profile 133 pazopanib hydrochloride - Drug Profile 141 pembrolizumab - Drug Profile 148 racotumomab - Drug Profile 185 RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile 187 roneparstat - Drug Profile 188 S-588410 - Drug Profile 189 Small Molecules for Ewing Sarcoma - Drug Profile 191 SP-2509 - Drug Profile 192 SP-2528 - Drug Profile 193 SP-2577 - Drug Profile 194 TK-216 - Drug Profile 195 Vimo-101 - Drug Profile 196 Ewing Sarcoma - Dormant Projects 197 Ewing Sarcoma - Discontinued Products 199 Ewing Sarcoma - Product Development Milestones 200 Featured News & Press Releases 200 Appendix 207 Methodology 207 Coverage 207 Secondary Research 207 Primary Research 207 Expert Panel Validation 207 Contact Us 207 Disclaimer 208
List of Tables
Number of Products under Development for Ewing Sarcoma, H2 2016 11 Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2016 20 Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H2 2016 21 Ewing Sarcoma - Pipeline by Cebiotex, S.L., H2 2016 22 Ewing Sarcoma - Pipeline by Celgene Corporation, H2 2016 23 Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2016 24 Ewing Sarcoma - Pipeline by Exelixis, Inc., H2 2016 25 Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2016 26 Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 27 Ewing Sarcoma - Pipeline by Merck & Co., Inc., H2 2016 28 Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 29 Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2016 30 Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016 31 Ewing Sarcoma - Pipeline by NantKwest, Inc., H2 2016 32 Ewing Sarcoma - Pipeline by Novartis AG, H2 2016 33 Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H2 2016 34 Ewing Sarcoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016 35 Ewing Sarcoma - Pipeline by Pfizer Inc., H2 2016 36 Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H2 2016 37 Ewing Sarcoma - Pipeline by Recombio S.L, H2 2016 38 Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016 39 Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2016 40 Assessment by Monotherapy Products, H2 2016 41 Number of Products by Stage and Target, H2 2016 43 Number of Products by Stage and Mechanism of Action, H2 2016 46 Number of Products by Stage and Route of Administration, H2 2016 49 Number of Products by Stage and Molecule Type, H2 2016 51 Ewing Sarcoma - Dormant Projects, H2 2016 199 Ewing Sarcoma - Dormant Projects (Contd..1), H2 2016 200 Ewing Sarcoma - Discontinued Products, H2 2016 201
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
